Malignant peripheral nerve sheath tumor development during MEK inhibitor treatment: A pre-clinical study and a clinical case series
{{output}}
Background: People with Neurofibromatosis type 1 (NF1) are at risk of developing benign and malignant peripheral nerve sheath tumors (MPNST). In NF1, the overall lifetime risk of MPNST is estimated at 8%-13%, with increased risk ... ...
